
AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody
AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
Newsletters and Deep Dive digital magazine
AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
After cutting staff and halting development of its CAR-T therapies, CARGO has agreed to a takeover by Kevin Tang's Concentra Bio.
Editor's Picks
Newsletters and Deep Dive
digital magazine